Welcome to our dedicated page for Jazz Pharmaceuticals Plc news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals Plc stock.
Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) is a global biopharmaceutical leader developing life-changing therapies for complex conditions in oncology, neuroscience, and sleep medicine. This dedicated news hub provides investors and healthcare professionals with timely updates on corporate milestones, regulatory developments, and clinical research advancements.
Our curated collection features official press releases, earnings reports, and analysis of strategic initiatives. Users can track key updates including FDA regulatory decisions, clinical trial results, and therapeutic portfolio expansions. The resource prioritizes accuracy and comprehensiveness, serving as a primary source for understanding Jazz's market position.
Content spans multiple categories essential for informed decision-making: product approvals, research collaborations, financial performance, and manufacturing updates. Each entry maintains strict editorial standards to ensure relevance to both clinical and investment communities.
Bookmark this page for streamlined access to Jazz Pharmaceuticals' latest developments. Check regularly for updates on innovative therapies addressing narcolepsy, epilepsy, and hematologic malignancies, supported by the company's established R&D expertise.
Jazz Pharmaceuticals (NASDAQ: JAZZ) has completed the acquisition of Chimerix for $935 million in cash, making Chimerix a wholly owned subsidiary. The deal centers around dordaviprone, a novel first-in-class small molecule treatment for H3 K27M-mutant diffuse glioma.
The drug is currently under FDA Priority Review with a PDUFA date of August 18, 2025. If approved, it could become the first FDA-approved therapy for this condition and may qualify for a Rare Pediatric Disease Priority Review Voucher. The acquisition price was set at $8.55 per share in cash.
Dordaviprone is also being evaluated in the Phase 3 ACTION trial for newly diagnosed, non-recurrent H3 K27M-mutant diffuse glioma patients post-radiation treatment, potentially expanding its use to first-line treatment.
Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced its participation in the 24th Annual Needham Healthcare Conference. The company's management will engage in a fireside chat scheduled for Wednesday, April 9, 2025, at 9:45 a.m. PT / 12:45 p.m. ET / 5:45 p.m. IST.
An audio webcast of the discussion will be accessible through the Investors section of Jazz Pharmaceuticals' website, with replays available for 30 days. The company, headquartered in Dublin, Ireland, is a global biopharma organization focused on developing life-changing medicines for patients with serious diseases, particularly in areas with therapeutic options.
Jazz maintains a diverse portfolio including:
- Leading therapies for sleep disorders and epilepsy
- Growing portfolio of cancer treatments
- Innovative therapeutics pipeline in oncology and neuroscience
Jazz Pharmaceuticals (JAZZ) has announced the presentation of seven abstracts from its neuroscience portfolio at the 77th Annual American Academy of Neurology Meeting in April 2025. Key highlights include updated results from the Phase 4 DUET trial for Xywav® oral solution, showing statistically significant improvements in patients with narcolepsy and idiopathic hypersomnia (IH).
The DUET trial demonstrated notable improvements in Epworth Sleepiness Scale scores, reduced sleep stage shifts, increased deep sleep, and reduced awakenings in adults with narcolepsy. For IH patients, improvements were observed in ESS and Idiopathic Hypersomnia Severity Scale scores.
Additionally, a novel analysis of Epidiolex® real-world treatment patterns revealed nearly 70% persistence rate at one year among new patients. The data showed that 52% of patients took dosages >15 mg/kg/day at 12 months, with those taking >20 mg/kg/day showing the lowest discontinuation rates.
Jazz Pharmaceuticals (JAZZ) has announced the acquisition of Chimerix for $8.55 per share, representing a total cash consideration of $935 million - a 72% premium over Chimerix's closing price on March 4, 2025. The transaction is expected to close in Q2 2025.
The acquisition centers on dordaviprone, Chimerix's lead clinical asset, a first-in-class treatment for H3 K27M-mutant diffuse glioma, a rare brain tumor affecting children and young adults. The FDA has granted Priority Review for dordaviprone with a PDUFA date of August 18, 2025. If approved, it would be the first FDA-approved therapy specifically for this condition.
The drug is also being evaluated in the ongoing Phase 3 ACTION trial for newly diagnosed patients. Jazz plans to leverage its development and commercial capabilities for a potential launch in the second half of 2025, with patent protection extending to 2037.
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported strong financial results for 2024, achieving record total revenues of $4.1 billion, a 6% year-over-year growth. The company's Q4 2024 revenues reached $1.1 billion.
Key performance highlights include:
- Xywav revenues grew 16% to $1.47 billion in 2024
- Epidiolex revenues increased 15% to $972.4 million
- Oncology revenues surpassed $1.1 billion, growing 9%
- GAAP net income was $560.1 million ($8.65 per diluted share)
- Non-GAAP adjusted net income reached $1.37 billion ($20.90 per diluted share)
The company generated $1.4 billion in cash from operations and ended 2024 with $3.0 billion in cash and investments. For 2025, Jazz provided revenue guidance of $4.15-$4.40 billion, representing 5% growth at the midpoint.
Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced its participation in TD Cowen's 45th Annual Health Care Conference. The company's management will engage in a fireside chat scheduled for March 5, 2025, at 7:30 a.m. PT / 10:30 a.m. ET / 3:30 p.m. GMT.
The event will be accessible via audio webcast through the Investors section of Jazz Pharmaceuticals' website, with recordings available for 30 days post-event. Jazz Pharmaceuticals is a global biopharma company focused on developing life-changing medicines for patients with serious diseases, particularly in areas with therapeutic options.
The company maintains a diverse portfolio of marketed medicines, specializing in sleep disorders and epilepsy treatments, along with an expanding cancer treatment portfolio. Their research and development efforts span both oncology and neuroscience, with operations and facilities across multiple countries, headquartered in Dublin, Ireland.
Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced it will release its 2024 full year and fourth quarter financial results on Tuesday, February 25, 2025, after U.S. market close. The company will host a live audio webcast at 4:30 p.m. ET to discuss the results and provide business updates.
The webcast will be accessible through Jazz Pharmaceuticals' Investor Relations website, with dial-in numbers available for U.S. (+1 800 715 9871) and Ireland (+353 1800 943 926) participants. Interested parties are advised to register 15 minutes before the scheduled webcast.
Jazz Pharmaceuticals is a global biopharma company focused on developing life-changing medicines for serious diseases, with a portfolio including therapies for sleep disorders, epilepsy, and cancer treatments.
Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Chairman and CEO Bruce Cozadd will deliver a corporate presentation and business update on January 14, 2025, at 9:45 a.m. PST.
The presentation will be accessible via webcast through the Investors section of Jazz Pharmaceuticals' website, with a replay available for 30 days post-conference. Jazz Pharmaceuticals is a global biopharma company focused on developing life-changing medicines for serious diseases, particularly in sleep disorders, epilepsy, and cancer treatments. The company maintains its headquarters in Dublin, Ireland, with research, development, and manufacturing facilities across multiple countries.
Jazz Pharmaceuticals (NASDAQ: JAZZ) announced that CEO Bruce Cozadd plans to retire by the end of 2025, while continuing as Board Chair. The company's Board will conduct a comprehensive internal and external search for his successor, expected to conclude within 12 months.
Cozadd co-founded Jazz in 2003 and has served as CEO since 2009, transforming it into a global biopharmaceutical company with a focus on neuroscience and oncology. Under his leadership, the company grew to expect $4.0-4.1 billion in total revenue for 2024. Jazz currently employs approximately 2,800 people globally and maintains a commercialized portfolio with a differentiated pipeline of assets.
Jazz Pharmaceuticals (JAZZ) presented nine company-sponsored Epidiolex® (cannabidiol) posters at the American Epilepsy Society 2024 Annual Meeting. The presentations include real-world evidence from multiple studies showcasing the drug's effectiveness in treating rare epilepsies.
Key findings include: improvements in behavioral symptoms from the EpiCom trial; positive outcomes from the BECOME-TSC survey where 89% of caregivers plan to continue treatment; and results from the BECOME-LTC survey showing 85% of nurses reported reduced seizure frequency, with 49% noting over 50% reduction. The data also demonstrated Epidiolex's effectiveness in treating tuberous sclerosis complex (TSC), with median seizure reductions of 51%-87% in focal seizures and 44%-87% in total seizures.
FAQ
What is the current stock price of Jazz Pharmaceuticals Plc (JAZZ)?
What is the market cap of Jazz Pharmaceuticals Plc (JAZZ)?
